AI biotech (formerly VantAI) that designs induced-proximity drugs, small molecules that bring together or separate proteins.
Founders
Zachary Carpenter(United States · ♂)— A Columbia genomics PhD and Roivant computational discovery head who spun Proxima (formerly VantAI) out of Roivant in 2019 to use AI to design proximity-based medicines.
Luca Naef(Switzerland · ♂)— An ETH Zurich molecular biology and deep-learning researcher from an engineering family who met Carpenter at McKinsey Digital and co-founded VantAI/Proxima as CTO to build AI-native drug discovery.
In the network
Shares the most investors with (number = shared investors):
New York-based Proxima (formerly VantAI) emerged from stealth with an $80 million seed led by DCVC with Nvidia's NVentures for its 'molecular matchmaker' drugs.
$80M
Investors
Tap an investor to see what else they have backed.